thinkpool

​

​

​Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update
December 01 2021 - 06:45PM
Business Wire
Alert
Print
Share On Facebook
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021.

The peer-reviewed paper in The Lancet Respiratory Medicine is available via the follow link: https://doi.org/10.1016/S2213-2600(21)00494-X

The associated comment in The Lancet Respiratory Medicine is available via the following link: https://doi.org/10.1016/S2213-2600(21)00539-7

Details about how to access the conference call and webcast are provided below:

Webcast Link: https://event.on24.com/wcc/r/3546628/89B026371EFD46CB1F47B869C82E1992

The webcast will be available for up to one year under the Events & Presentations section of Humanigen’s Investor Relations website at https://ir.humanigen.com/English/events-and-presentations/

Dial by Phone:
United States (Toll Free): (844)-200-6205

All other locations: +1 (929)-526-1599

Access code: 259894

About Humanigen, Inc.

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ?cytokine storm’. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. Early in the COVID-19 pandemic, investigation showed high levels of GM-CSF secreting T cells were associated with disease severity and intensive care unit admission. Humanigen’s Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent cytokine storm in hospitalized patients with COVID-19. Humanigen has submitted lenzilumab to Medicines and Health Regulatory Agency in the United Kingdom for a rolling review towards potential Conditional Marketing Authorization. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook. 

 

 


View source version on businesswire.com: https://www.businesswire.com/news/home/20211201006217/en/

Humanigen Investor Relations
Ken Trbovich
Humanigen
trbo@humanigen.com
650-410-3206        

​

​Humanigen, 전화 회의 및 웹캐스트를 발표하여 Lancet Respiratory Medicine 출판물에 대해 논의하고 기업 업데이트를 제공
2021년 12월 1일 - 06:45PM
비즈니스 와이어
경보
인쇄
Facebook에서 공유
'사이토카인 스톰'이라는 면역초반응 예방 및 치료에 주력하는 임상단계 바이오제약 기업 후마니젠(이하 후마니젠)이 오는 2021년 12월 2일 오전 8시 란셋 호흡기 의학 출판물을 논의하고 기업 업데이트를 제공하는 컨퍼런스콜과 웹캐스트를 진행한다고 밝혔다..

The Lancet Respiratory Medicine의 동료 보호 논문은 다음 링크를 통해 제공됩니다.https://doi.org/10.1016/S2213-2600(21)00494-X

Lancet Respiratory Medicine의 관련 의견은 다음 링크를 통해 제공됩니다.https://doi.org/10.1016/S2213-2600(21)00539-7

전화 회의 및 웹캐스트에 액세스하는 방법에 대한 자세한 내용은 다음과 같습니다.

웹캐스트 링크:https://event.on24.com/wcc/r/3546628/89B026371EFD46CB1F47B869C82E1992

이 웹캐스트는 Humanigen의 투자자 홍보 웹 사이트 이벤트 & 프레젠테이션 섹션에서 최대 1년간 제공됩니다.https://ir.humanigen.com/English/events-and-presentations/

전화로 전화 걸기:
미국(톨 프리): (844)-200-6205

기타 모든 위치: +1 (929)-526-1599

액세스 코드: 259894